Session Details
Oral Presentation（Esophagus） 3 Neoadjuvant treatment/Prognostic factor
Fri. Oct 24, 2025 10:50 AM - 11:50 AM JST
Fri. Oct 24, 2025 1:50 AM - 2:50 AM UTC
Fri. Oct 24, 2025 1:50 AM - 2:50 AM UTC
Main Hall, 5 fl, Osaka International Convention Center
座長：土岐 祐一郎(大阪大学 消化器外科), 塩崎 敦(京都府立医科大学 外科学教室 消化器外科部門)
[EOP3-1]Immunochemotherapy versus chemoradiotherapy as induction therapy followed by conversion surgery for unresectable stage cT4 esophageal squamous cell carcinoma【Best Paper Award】
Dong Tian1 (1.Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China, 2.Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan, 3.Department of Thoracic Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China)
[EOP3-2]Tislelizumab Plus Chemotherapy versus Triplet Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-III Esophageal Squamous Cell Carcinoma：Preliminary Results of a Randomized Phase II Trial
Lilan Zhao1 (1.Department of Thoracic Surgery, Fuzhou University Affiliated Provincial Hospital, Fuzhou University, Fuzhou, Fujian Province, China, 2.Department of Gastrointestinal and Esophageal Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China, 3.Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China)
[EOP3-3]Long-Term Survival and Treatment Patterns in Resectable Esophageal Squamous Cell Carcinoma in East Asia：A Comprehensive Study from the International Esodata Study Group（Dragon Study）
Xuefeng Leng1 (1.Sichuan Cancer Hospital ＆ Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China（UESTC）, Chengdu, China, 2.National Cancer Center Hospital, Tokyo, Japan, 3.Shanghai Chest Hospital, Shanghai, China, 4.Queen Mary Hospital, Hong Kong University, Hong Kong, China, 5.Samsung Medical Center, Seoul, Korea, 6.Virginia Mason Medical Center, Seattle, USA)
[EOP3-4]Utility of initial reduction of metastatic lymph nodes in patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery
Takaomi Hagi1,2, Osamu Shiraishi2, Masuhiro Terada2, Atsushi Yamada2, Masashi Kohda2, Tomoya Nakanishi2, Yoko Hiraki2, Hiroaki Kato2, Atsushi Yasuda2, Masayuki Shinkai2, Motohiro Imano2, Takushi Yasuda2 (1.Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan, 2.Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan)
[EOP3-5]Intratumoral and Peritumoral Radiomics-based Machine Learning Models for the Survival Prediction in Esophageal Squamous Cell Carcinoma after Surgery
Zhi Qiang Deng1 (1.Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China, 2.Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan, 3.College of Medical Imaging, North Sichuan Medical College, Nanchong, China, 4.Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China)
[EOP3-6]Comparison of the prognostic value of LODDS and N stage for esophageal squamous cell carcinoma patients treated with neoadjuvant immunochemotherapy：a multicenter retrospective study
Feng Wang (Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University；Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China)